The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR -Mutant NSCLC Patients Treated with First-Line Osimertinib.
Kuan-Chih ChenYen-Hsiang HuangKuo-Hsuan HsuJeng-Sen TsengGee-Chen ChangTsung-Ying YangPublished in: OncoTargets and therapy (2023)
-mutant NSCLC patients receiving first-line osimertinib. A high NLR was associated with higher metastatic burden, more extrathoracic metastases, and therefore, a worse outcome.